Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60â¯years and has lower toxicities: Comparison with low-dose chemotherapy.
Blood Cells Mol Dis
; 77: 88-94, 2019 07.
Article
em En
| MEDLINE
| ID: mdl-31005752
ABSTRACT
Decitabine and low-dose chemotherapy are common treatments for intermediate and high risk myelodysplastic syndromes (MDS). In this study, we retrospectively assessed the efficacy and toxicity of the two regimens for MDS-refractory anemia with excess blasts (MDS-RAEB) patients. A total of 112 patients with a diagnosis of MDS-RAEB are included. The overall response (OR) and complete remission (CR) rate was comparable between the two groups (OR 64.1% vs. 66.7%, pâ¯=â¯0.60; CR 23.4% vs. 31.3%, pâ¯=â¯0.64). The OR rates of 20â¯mg/m2/day and 15â¯mg/m2/day decitabine regimen were comparable (69.0% vs. 60.0%, pâ¯=â¯0.46). Overall survival (OS) did not differ significantly between the groups (20.7 vs. 13.5â¯months, pâ¯=â¯0.17). In a subgroup analysis that included only patients at ≥60â¯years of age, survival benefit of decitabine was apparent (20.6 vs. 10.0â¯months, pâ¯=â¯0.03). In hematological toxicities, the lowest count of platelet in the decitabine group was higher significantly. And, the incidence of Grade 3-4 infection in the decitabine group was lower significantly. Our results demonstrate that both decitabine and low-dose chemotherapy are effective for MDS-RAEB, but decitabine was safer. Decitabine might be a better choice for patients at ≥60â¯years of age.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Anemia Refratária com Excesso de Blastos
/
Decitabina
/
Antimetabólitos Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Blood Cells Mol Dis
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
China